A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting 105 enrolled Verastem, Inc.

RandomizedCrossoverSingle-blindTreatment

Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Timeline

Start: 2026-06
Primary completion: 2027-06
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VS-7375	Small molecule	—	Oral

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications